Phase 1 × Completed × Leukemia, Lymphocytic, Chronic, B-Cell × Clear all Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
Phase 1 Completed
3 enrolled
ATECRAB
Phase 1 Completed
3 enrolled
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
Phase 1 Completed
7 enrolled
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Phase 1 Completed
69 enrolled
Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
Phase 1 Completed
3 enrolled 8 charts
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
Phase 1 Completed
35 enrolled
ELM-1
Phase 1 Completed
200 enrolled
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Phase 1 Completed
26 enrolled
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Phase 1 Completed
85 enrolled
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
Phase 1 Completed
45 enrolled
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Phase 1 Completed
226 enrolled
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
Phase 1 Completed
38 enrolled 14 charts
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Phase 1 Completed
34 enrolled 14 charts
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
Phase 1 Completed
8 enrolled
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
Phase 1 Completed
95 enrolled
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 1 Completed
14 enrolled
Personalized Multi-peptide Vaccination in CLL Patients
Phase 1 Completed
20 enrolled
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Phase 1 Completed
45 enrolled 13 charts
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Phase 1 Completed
154 enrolled
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Phase 1 Completed
20 enrolled
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies
Phase 1 Completed
71 enrolled
LAM-002A/NHL
Phase 1 Completed
62 enrolled 20 charts
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Phase 1 Completed
18 enrolled
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1 Completed
16 enrolled
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Phase 1 Completed
43 enrolled
Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma
Phase 1 Completed
7 enrolled
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
Phase 1 Completed
5 enrolled
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Phase 1 Completed
91 enrolled
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Phase 1 Completed
34 enrolled
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Phase 1 Completed
29 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase 1 Completed
16 enrolled
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Phase 1 Completed
15 enrolled
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
35 enrolled
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell
Phase 1 Completed
26 enrolled 10 charts
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
Phase 1 Completed
26 enrolled 10 charts
Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial
Phase 1 Completed
9 enrolled
Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma
Phase 1 Completed
8 enrolled
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Phase 1 Completed
49 enrolled
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Phase 1 Completed
14 enrolled
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
11 enrolled
Intermittent Fasting and CLL/SLL
Phase 1 Completed
15 enrolled
BRiM
Phase 1 Completed
11 enrolled 20 charts
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Phase 1 Completed
286 enrolled 26 charts
A Study of BNC105P Combined With Ibrutinib
Phase 1 Completed
6 enrolled
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
Phase 1 Completed
27 enrolled
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Completed
27 enrolled
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
Phase 1 Completed
26 enrolled
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Phase 1 Completed
222 enrolled
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
Phase 1 Completed
44 enrolled
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Phase 1 Completed
118 enrolled